Q1 2025 Earnings Call Transcript May 2, 2025 Jo Russell: Good morning, everyone, and welcome to conference call for our first ...

Q1 2025 Results Conference Call April 30, 2025 3:30 PM ETCompany ParticipantsJo Russell - Head-Investor RelationsDawn Allen - ...

A common cause of phlegm is something called a post-nasal drip. This sounds horrible ... Treatment is with a nose spray (eg Beconase or Flixonase) containing a very dilute dose of steroid (which ...

LTR Pharma (ASX:LTP) has joined forces with Strategic Drug Solutions to developed a nasal spray to treat oesophageal motility disorders.

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

Spring is a miserable season for those with seasonal allergies. There are effective drug- and non-drug measures that can ...

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first needle-free alternative to EpiPen-style autoinjectors for serious allergic reactions. The green light ...